x
ServiziMenu principaleHome
You are here: Home > Events > Past events > 2019 > Eastern Europe and Balkan Region Refresher Course on Lung Cancer
Print

Eastern Europe and Balkan Region Refresher Course on Lung Cancer

28.03.2019  -  30.03.2019

Budapest, Hungary

ADVANCED COURSES & SEMINARS

Lung cancer

Description

Chairs: T. Cufer, SI – E. Felip, ES


The Refresher Course on Lung Cancer is designed for medical and clinical oncologists of the Eastern Europe and Balkan Region in order to provide an update on the state-of-the-art therapeutic options as well as an overview of the latest advances in the field of lung cancer.

The programme will offer educational lectures covering updates and future directions in diagnostic and treatment approaches in lung cancer; while real life case discussions will provide an ideal opportunity for multidisciplinary discussion. By presenting real life cases young oncologist will get an ideal opportunity to learn on how to best present and discuss their cases.

LEARNING OBJECTIVES
• Update on pathology and molecular testing in lung cancer
• Update on the latest advances in diagnostic procedures
• Update on the latest advances in targeted therapy and immunotherapy for lung cancer
• Update on modern surgical and radiation therapy approaches in lung cancer
• Get acquainted and put into perspective the latest guidelines
• Learn about the management of specific situations on lung cancer
• Debate controversies and challenges in lung cancer treatment
• Improve practical skills in multidisciplinary discussion and management of lung cancer patients

Faculty

FACULTY
T. Cufer, University Clinic Golnik, SI
E. Felip, Vall d'Hebron University Hospital, Barcelona, ES
G. Galffy, Semmelweis University, Budapest; Pest County Pulmonology Hospital, Törökbálint, HU
M. A. Hoda, Medical University Vienna, Vienna, AT
D. Jovanovic, University Hospital of Pulmonology, Belgrade, RS
L. Kepka, Military Institute of Medicine, Warsaw, PL
I. Kern, University Clinic Golnik, Golnik, SI
G. Ostoros, Semmelweiss University, Budapest, HU
H. Ringl, Medical University Vienna, Vienna, AT



General information

ORGANISING SECRETARIAT
European School of Oncology (ESO)
Piazza Indipendenza 2
6500 Bellinzona
Laura Richetti,
ph +41 91 820 09 51, e-mail: lrichetti@eso.net
Dolores Knupfer, ph +41 91 820 09 52, e-mail: dknupfer@eso.net

OFFICIAL LANGUAGE
The official language will be English. No translation will be available.

CME ACCREDITATION
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value. The event is designated for a maximum of 10 European CME credits (ECMEC). Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.

Application

PARTICIPANT’S PROFILE
• Age between 30 and 45 years
• 2-4 years’ experience in oncology
• Involvement in scientific activities and clinical trials
• Fluency in English
• Practicing in Eastern Europe and Balkan Region

PARTICIPATION
Attendance is limited and admittance is by competitive application only.
Successful applicants are granted free registration, lunches and coffee breaks.
Free accommodation at the course venue for arrival on 28 March and departure on 30 March will be provided to participants not residing in the Budapest area.

Priority will be given to applicants who have attended a previous Eastern Europe and Balkan Region Masterclass.

The application outcome will be notified by e-mail by 1st February 2019.

ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
THE APPLICATION DEADLINE HAS PASSED (14 JANUARY 2019)

Programme

28 March

18:00 Arrivals

29 March

8:45 Welcome address and general introduction
9:00 Screening for lung cancer: pros and cons
M.A. Hoda, AT
9:30 Histopathological diagnosis and classification of lung cancer
I. Kern, SI
10:00 Molecular testing at primary diagnosis and during treatment
I. Kern, SI
10:30 Coffee break
11:00 Radiological methods to assist primary diagnostics and treatment tailoring
H. Ringl, AT
11:30 Adjuvant/neoadjuvant systemic therapy: Any news?
G. Ostoros, HU
12:00 Lunch
13:30 Radiotherapy in combination with systemic therapies – a final answer for Stage III disease?
L. Kepka, PL
14:00 Stereotactic radiotherapy - how to proceed in lung cancer?
L. Kepka, PL
14:30 Surgery of lung cancer: opportunities and limitations
M.A. Hoda, AT
15:00 Coffee break
15:30 Cases presented by participants and discussed by tumor board (faculty) (17:30)

30 March

8:30 Update on current standards in SCLC therapy
G. Ostoros, HU
9:00 Novel targets and targeted therapies in development
E. Felip, ES
9:30 New frontiers in immunotherapy of lung cancer
E. Felip, ES
10:00 Coffee break
10:30 Everyday clinical practice questions provided in written form by participants and discussed by tumor board (faculty)
11:30 Update on current standards in targeted therapy in advanced NSCLC
T. Cufer, SI
12:00 Update on current standards in immunotherapy in NSCLC
G. Galffy, HU
12:30 Management of oligometastatic lung cancer -dilemmas and opportunities
D. Jovanovic, RS
13:00 Closing remarks

 

Follow us